Abbott Laboratories


SKU: ABT-1 Category:


Abbott Laboratories reported a very strong first-quarter of 2021 driven by the ongoing increase in sales of Covid-19 diagnostics and the surge in testing activity. Notably, the U.S. Food and Drug Administration (FDA) recently granted Abbott the emergency use authorization for an at-home version of the BinaxNOW. Also, BinaxNOW recently became available in an array of drugstores as an over-the-counter version launched in Walmart, Walgreens, and CVS Health Retail outlets. Unlike last year when Abbot’s medical unit sales were hit badly, the recent result saw revenue growth in almost all categories (except cardiac failure) which is a major green flag. Over and above its product applications in Covid-19, Abbott’s management plans to launch some major products in 2021 including Amulet, an occlusion device is used to seal off the left atrial appendage and is suitable for patients who are at risk of a stroke. The product is already cleared for use in international markets. Overall, the company is poised for a strong year ahead.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $496 annual subscription!